Vector Immunogenicity and Redosing Patents: Leaders & Trends 2026
- 21.5% concentration at the top. The five leading assignees hold 2,701 of 12,584 records in scope — a concentrated core with a long tail behind it.
- Filings peaked in 2021 at 1,021, then fell to 524 by 2024. a 49% decline over that three-year span, even before the most recent, still-incomplete years are counted.
- A61K and C07K dominate the technology mix. 75.1% and 66.0% of records respectively, leaving analytical and enzymatic sub-classes comparatively thin.
Filing growth compares 2021 (1,021 records) with 2024 (524) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 12,584 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Vector immunogenicity and redosing sits at the intersection of gene therapy delivery and immune tolerance: patents here cover capsid engineering to blunt neutralizing antibody responses, immunosuppression regimens that permit repeat dosing, and diagnostic methods such as seroprevalence testing that screen patients for preexisting immunity before a vector is administered. The search spans preexisting immunity, complement activation, empty capsid decoy strategies and related redosing approaches, filtered against core immunogenicity terms.
12,584 published records fall within scope, spanning filings from 2015 through the 2026 cut-off. Publication lags filing by roughly 18 months, so the most recent one to two years in any trend chart will always look thinner than they eventually turn out to be.
Filing trends and technology composition
Two views of the same 12,584-record corpus: how filing volume moved year over year, and how records distribute across IPC subclasses.
Filing trend, 2017-2026
Filings rose from 674 in 2017 to a peak of 1,021 in 2021, then declined to 524 by 2024 — a 49% drop over that three-year span. 2025 and 2026 figures are still filling in under the usual publication lag and should not be read as a continued decline.
Technology composition by IPC subclass
A61K (medicinal preparations) and C07K (peptides & proteins) each cover more than two-thirds of records, reflecting a field still organized around formulation and protein-engineering claims rather than around analytical or enzymatic methods, which remain comparatively under-filed.
Shares are the percentage of the 12,584 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Vector Immunogenicity and Redosing with Eureka
This page is one run against one query. Ask Eureka your own question about vector immunogenicity and redosing and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Methods and compositions for using plasma cell depleting agents and/or B cell depleting agents to suppress host Anti-AAV antibody response and enable AAV transduction and re-dosing
Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or population of cells, methods of expressing that polypeptide, and methods of treating or preventing an enzyme deficiency. Where a subject has preexisting immunity against an immunogen to be administered, the methods use plasma cell depleting agents, alone or in combination, to mitigate the immune response and enable transduction or re-dosing.Filed by Regeneron Pharmaceuticals; published 2025-07-31.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7527791B2 | Humanized anti-TGF-beta antibodies | 2,278 |
| 2 | US20080069820A1 | Multispecific antibodies | 2,034 |
| 3 | WO2013132044A1 | Combination therapy of antibodies against human CSF-1r and uses thereof | 845 |
| 4 | WO2003042397A2 | A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences… | 776 |
| 5 | US20120301498A1 | Controlled release of immunosuppressants from synthetic nanocarriers | 757 |
| 6 | WO2001083692A2 | Recombinant AAV vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids | 700 |
| 7 | US5494807A | NYVAC vaccinia virus recombinants comprising heterologous inserts | 653 |
| 8 | WO2013119716A1 | Compositions and methods for using CSF1r inhibitors | 652 |
| 9 | WO2005063816A2 | Monovalent antibody fragments useful as therapeutics | 556 |
| 10 | WO2011133886A2 | Production of heteromultimeric proteins | 553 |
Citation counts reflect influence within the searched corpus and skew toward older filings; treat them as a signal of prior-art density, not current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Three patterns stand out once the filing and citation data are put side by side.
A concentrated core, not a monopoly
The five leading assignees account for 21.5% of all records in scope, and the next five bring the top-10 combined share to 31.0%. That leaves the majority of filings spread across a long tail of single- and few-filing entrants — a field with clear leaders but real room for new claims.
Peak filing has passed, for now
Filings rose steadily to a peak of 1,021 in 2021, then fell to 524 by 2024. That reads as consolidation around established approaches rather than a slowdown in the underlying science, since redosing and immunogenicity remain active clinical problems.
Formulation claims dominate the mix
Medicinal-preparation claims (A61K) and peptide/protein claims (C07K) each cover most of the corpus, while measurement and enzymatic sub-classes such as C12Q and C07H sit under 5%. Dense formulation coverage does not mean the underlying biology is settled — it means that particular claim space is occupied.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to vector immunogenicity and redosing, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked leaders combine large biopharma, an academic technology-transfer program and specialist immunosuppression and nanocarrier developers. Recent-year momentum, however, is negative across nearly every one of them, which says more about the publication lag than about a genuine retreat from the field.
Even active filers show a dip
Assignees with a strong filing history show sharp year-over-year declines in the latest year — a pattern consistent with publication lag rather than a real pullback, since 2025-2026 records are still being published.
Collaboration is limited but visible
Ten co-assignee pairs appear in the data, with the strongest linking an academic institution to a commercial partner and a biologics maker to a government research body — evidence of applied translational partnerships rather than broad industry consortia.
Filing strategy centers on US, EPO and PCT
The United States leads as receiving office, followed by the European Patent Office and WIPO's PCT route, with Australia, Israel and Canada trailing. That ordering points to a field still prioritizing the largest pharmaceutical markets over broad multi-jurisdiction filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals | 4 | -79% |
| The Trustees of the University of Pennsylvania | 2 | -82% |
| CureVac SE | 2 | -85% |
| Gilead Sciences, Inc. | 1 | -67% |
| Genentech, Inc. | 0 | -100% |
| Selecta Biosciences, Inc. | 0 | — |
| GlaxoSmithKline Biologicals SA | 0 | -100% |
| Annexon, Inc. | 0 | — |
Where to take this next
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy or competitive tracking.
Check freedom-to-operate against the dense classes
A61K and C07K carry the bulk of claims; a formulation or protein-engineering approach should be checked against this crowded space before drafting.
Explore claim density in EurekaTrack momentum shifts as 2025-2026 data fills in
Current year-over-year drops likely reflect publication lag rather than a real slowdown; revisit assignee momentum once later years mature.
Set up momentum tracking in EurekaScope the under-claimed branches
Seroprevalence assay standardization and complement-activation biomarkers show thinner coverage than the core formulation classes — a plausible entry point for new claims.
Map white space in EurekaCommon questions
It refers to patent claims covering how the immune system responds to viral vectors like AAV, and to methods that allow a second or later dose to work despite that response. This includes capsid engineering to reduce neutralizing antibody binding, immunosuppression regimens administered around dosing, seroprevalence testing to screen patients beforehand, and empty capsid decoy strategies that absorb existing antibodies. The 12,584 records in this landscape combine these approaches with underlying antibody and complement-activation science.
Filings concentrate at the top: the five leading assignees together hold 21.5% of the 12,584 records in scope, and the top ten hold 31.0%. The ranking includes large biopharmaceutical companies, an academic technology-transfer program, and specialist developers of nanocarrier and immunosuppression platforms. Beyond the leaders, filings spread across a long tail of companies with only a handful of records each, meaning the field is not a closed monopoly.
Filings peaked in 2021 at 1,021 and fell to 524 by 2024, a 49% decline over that span. That decline should be read carefully: publication typically lags filing by around 18 months, so 2025 and 2026 figures in this dataset are still incomplete and cannot yet be treated as evidence of a continued slowdown. The 2017-2021 run-up shows the field was still actively expanding claim coverage through that period.
The technology mix skews heavily toward formulation (A61K, 75.1% of records) and peptide/protein claims (C07K, 66.0%), while analytical and enzymatic sub-classes such as C12Q and C07H each cover under 5% of records. That gap suggests seroprevalence assay standardization, complement-activation biomarker methods, and structured immunosuppression dosing schedules remain comparatively under-claimed relative to the crowded formulation core.
US20250242056A1, filed by Regeneron and published 2025-07-31, covers methods using plasma cell depleting agents and B cell depleting agents to suppress a host's anti-AAV antibody response so that AAV transduction or redosing can proceed despite preexisting immunity. It is built around gene-insertion methods for treating enzyme deficiencies. Anyone designing a redosing protocol involving B cell or plasma cell depletion for AAV therapies should review this filing's claim scope directly rather than relying on the abstract alone.
Research Vector Immunogenicity and Redosing in depth with Eureka
Go past this page: query the whole vector immunogenicity and redosing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.